Oragenics Regains NYSE Compliance, Resolves Stockholder Equity Deficiency

Oragenics has regained full compliance with NYSE American's listing standards, resolving a stockholder equity deficiency of at least $6 million. The company regained compliance on October 20, 2025, and the "BC" indicator will be removed. Oragenics can now focus on advancing its lead clinical program.

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing unique, intranasal pharmaceuticals for neurological disorders, has regained full compliance with NYSE American's listing standards. The company resolved a stockholder equity deficiency of at least $6 million and removed the "BC" indicator from its listing status on October 20, 2025. This resolution allows Oragenics to focus on advancing its lead clinical program, the ONP-2 concussion treatment.

The company had previously faced regulatory challenges due to the stockholder equity deficiency, which required immediate attention. With the issue resolved, Oragenics can now direct its resources towards its core mission of developing innovative treatments for neurological disorders. The resolution of the equity deficiency also signals a positive step for the company's financial health, potentially boosting investor confidence.

In addition to the equity compliance, Oragenics has recently announced a public offering of up to 800,000 shares of its Series H Convertible Preferred Stock and accompanying Warrants, aiming to raise $20 million for clinical trials and operations. The offering, managed by Dawson James Securities, is set to close around July 2, 2025, pending customary conditions Oragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and Warrants^[1].

The funds raised from the offering will be used to support the ONP-2 concussion clinical trials, repay a $3 million bridge note, and for general working capital purposes. The offering is being conducted under an effective registration statement with the SEC, ensuring regulatory compliance and transparency for potential investors.

The successful resolution of the stockholder equity deficiency and the ongoing clinical trials are significant milestones for Oragenics. The company's focus on advancing its lead clinical program and securing necessary funding positions it well for future growth and innovation in the neurological disorder treatment space.